Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study

R. K. Kelley, C. Verslype, A. L. Cohn, T. S. Yang, W. C. Su, H. Burris, F. Braiteh, N. Vogelzang, A. Spira, P. Foster, Y. Lee, Eric Van Cutsem

研究成果: Article

57 引文 斯高帕斯(Scopus)

摘要

Background: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumortype cohorts. Patients and methods: Eligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS). Results: Among the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (> 50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients. Conclusions: Cabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions.

原文English
頁(從 - 到)528-534
頁數7
期刊Annals of Oncology
28
發行號3
DOIs
出版狀態Published - 2017 一月 1

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

指紋 深入研究「Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study」主題。共同形成了獨特的指紋。

  • 引用此

    Kelley, R. K., Verslype, C., Cohn, A. L., Yang, T. S., Su, W. C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., & Van Cutsem, E. (2017). Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study. Annals of Oncology, 28(3), 528-534. https://doi.org/10.1093/annonc/mdw651